Abstract
Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®, explained the use of tyrosine kinase inhibitors in the adjuvant setting in patients with advanced renal cell carcinoma, as well has how to best utilize immunotherapy in this setting.
